Sadie Stern Sells 2,565 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $88.37, for a total transaction of $226,669.05. Following the sale, the executive vice president owned 126,043 shares of the company’s stock, valued at $11,138,419.91. The trade was a 1.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Up 1.7%

DexCom stock opened at $90.82 on Friday. The firm has a market cap of $34.27 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 1.53 and a beta of 1.41. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The firm’s 50 day moving average price is $79.21 and its two-hundred day moving average price is $71.60. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.48 EPS. On average, research analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. BOKF NA boosted its holdings in DexCom by 175.7% during the fourth quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock valued at $2,344,000 after acquiring an additional 22,505 shares during the period. Plato Investment Management Ltd bought a new position in shares of DexCom in the second quarter worth about $782,000. Stephens Investment Management Group LLC increased its stake in shares of DexCom by 21.1% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock worth $69,211,000 after purchasing an additional 181,701 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in shares of DexCom during the 4th quarter worth about $3,231,000. Finally, Norges Bank acquired a new position in shares of DexCom during the 4th quarter worth about $483,356,000. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on DXCM shares. Deutsche Bank Aktiengesellschaft assumed coverage on DexCom in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target for the company. TD Cowen reaffirmed a “buy” rating on shares of DexCom in a research note on Friday, July 31st. Weiss Ratings upgraded shares of DexCom from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Benchmark lifted their target price on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Bank of America cut their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.